Royal Bank of Canada’s GSK GSK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-80
Closed -$4K 6926
2019
Q3
$4K Sell
80
-1,520
-95% -$78.2K ﹤0.01% 6091
2019
Q2
$80K Buy
1,600
+240
+18% +$12K ﹤0.01% 5000
2019
Q1
$71K Buy
1,360
+960
+240% +$48K ﹤0.01% 4978
2018
Q4
$19K Buy
+400
New +$19.7K ﹤0.01% 5614
2015
Q1
Sell
-40,000
Closed -$2.14M 6244
2014
Q4
$2.14M Hold
40,000
﹤0.01% 2288
2014
Q3
$2.3M Hold
40,000
﹤0.01% 2195
2014
Q2
$2.67M Hold
40,000
﹤0.01% 2075
2014
Q1
$2.67M Buy
+40,000
New +$2.7M ﹤0.01% 2040

Other funds holding GSK

Royal Bank of Canada's GSK Position: Q1 2026 in Review

Royal Bank of Canada reduced its GSK (GSK) stake by 11% in Q1 2026, selling an estimated $52.8M and leaving 7,506,786 shares worth $414M. The position accounts for 0.07% of the portfolio, ranked #251.

Royal Bank of Canada first reported a position in GSK in Q2 2013 and has held it in 52 quarters since. The position peaked at $958M in Q4 2013. 1,034 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Royal Bank of Canada held 7,506,786 shares of GSK worth $414M as of Q1 2026.
  • Royal Bank of Canada sold 973,760 GSK shares in Q1 2026, an estimated $52.8M.
  • GSK made up 0.07% of Royal Bank of Canada's portfolio in Q1 2026, its #251 holding.
  • Royal Bank of Canada first reported a position in GSK in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's GSK position peaked at $958M in Q4 2013.
  • 1,034 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.